Dr. Steven Pelech is the founder, president and C.S.O. of Kinexus and a full professor at the Univerity of British Columbia (UBC). He was previously the founder and president of Kinetek Pharmaceuticals. He completed his post-doctoral training with Sir Philip Cohen at the University of Dundee and Nobel laureate Dr. Edwin Krebs at the University of Washington in Seattle. He received his B.Sc. (1979; Honours) and Ph.D. (1982) degrees in Biochemistry from the UBC. Dr. Pelech has authored over 200 scientific publications in peer-reviewed journals and books about signal transduction and is one of the discoverers of the MAP kinase family of cell signalling proteins. He has served on review panels or has acted as an external reviewer for 29 granting agencies as well as an external reviewer for 28 scientific journals.
Christer Wingren graduated as a (bio)chemist (B.Sc.) at Lund University, Lund, Sweden in 1991. 1997 he received his Ph.D. in biochemistry at Lund University. His PhD thesis was on the surface properties of antibodies and antigen-antibody complexes. Dr. Wingren pursued his post-doctoral training in structural biology in the laboratory of Prof. Ian Wilson at the Scripps Research Institute, La Jolla, USA (1997-1999). Applying x-ray crystallography, he determined the 3D-structure of the γδ-TCR ligands T22 and T10. In 1999, Dr. Wingren joined the Dept. of Immunotechnology, Lund University, Sweden, headed by Prof. C. Borrebaeck. Initially, Dr. Wingren’s work was directed towards structural proteomics. Since 2000, Dr. Wingren directs a research group working on the development of recombinant antibody microarrays for high-throughput proteomics. Within these efforts, major work has been placed upon developing the basic protein array technology as well as designing applications within (disease) proteomics (protein expression profiling, biomarker discovery etc). In 2003, he was promoted to Associate Professor in Immunotechnology, and he now holds as position as a lecturer.